BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker ... before first securing EU regulatory approval. That prompted the commission, which acts as ...

The European Commission has approved, in accordance with the EU Mergers Regulation ("EUMR"), Illumina's plan to sell GRAIL after remedial measures requiring Illumina to terminate the completed ...

The EU regulators on Friday approved plans by U.S. genomics company Illumina (NASDAQ ... required the company to submit a divestment plan to the commission to approve the transaction.

BRUSSELS, Sept 6 (Reuters) - EU antitrust regulators plan to order ... a Reuters story in July. Illumina completed the deal in August last year ahead of EU regulatory approval, resulting in ...

The European Commission has approved Illumina's planned divestment of Grail, the sequencing company said Friday, although no divestment plan has been finalized. Illumina must capitalize Grail with ...

U.S. biotech firm Illumina was hit with a record antitrust fine of $476 million (€432 million) by the European Union Wednesday for failing to secure regulatory approval from the bloc for its $7. ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina (NASDAQ:ILMN)'s plan to divest cancer ... before first securing EU regulatory approval. That prompted the commission, which acts as ...

BRUSSELS, April 12 (Reuters) - U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test ... before first securing EU regulatory approval. That prompted the commission, which acts ...